{{Rsnum
|rsid=34223104
|Gene=CYP2B6
|Chromosome=19
|position=40991224
|Orientation=plus
|GMAF=0.01194
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP2B6
}}{{PharmGKB
|RSID=rs34223104
|Name_s=CYP2B6:(-82)C>T, defining SNP of CYP2B6*22
|Gene_s=CYP2A7P1, CYP2B6
|Feature=
|Evidence=PubMed ID:15722458
|Annotation=Risk or phenotype-associated allele: C. Phenotype: CYP2B6 mRNA expression and bupropion hydroxylase activity were approximately 2-fold higher in livers genotyped -82TC as in those genotyped -82TT. Study size: 85 (expression); 77 (activity). Study population/ethnicity: Non-tumorous liver samples from White individuals, Germany. Significance metric(s): p = 0.007 (expression); p = 0.042 (activity). Type of association: FA; PD
|Drugs=bupropion
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165282245
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs34223104
|overall_frequency_n=3
|overall_frequency_d=128
|overall_frequency=0.0234375
|n_genomes=3
|n_genomes_annotated=0
|n_haplomes=3
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}